ArticlePulmonary medicine2011
Macrophage-derived biomarkers of idiopathic pulmonary fibrosis.
Article in Pulmonary medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Bayesian-frequentist hybrid inference framework for single cell RNA-seq analyses.Human genomics · 2024Article
- Macrophages in Lung Repair and Fibrosis.Results and problems in cell differentiation · 2024Review
- Bayesian-frequentist hybrid inference framework for single cell RNA-seq analyses.Research square · 2023Article
- Clinical significance of interleukin-6, total bilirubin, CD3 + CD4 + T cells counts in the acute exacerbation of connective tissue disease-associated interstitial lung disease: a cross-sectional study.European journal of medical research · 2023Article
- iDESC: identifying differential expression in single-cell RNA sequencing data with multiple subjects.BMC bioinformatics · 2023Article
- Electronic Cigarette Exposure Enhances Lung Inflammatory and Fibrotic Responses in COPD Mice.Frontiers in pharmacology · 2021Article
- Serum levels of interleukins and S100A8/A9 correlate with clinical severity in patients with dermatomyositis-associated interstitial lung disease.BMC pulmonary medicine · 2020Article
- Could airway basal cells be a novel predictor of mortality in IPF?Breathe (Sheffield, England) · 2019Article
- Article
- A Mathematical Model of Idiopathic Pulmonary Fibrosis.PloS one · 2015Article
- Chitinase 3-like 1 suppresses injury and promotes fibroproliferative responses in Mammalian lung fibrosis.Science translational medicine · 2014Article
- Macrophage plasticity in skeletal muscle repair.BioMed research international · 2014Review
- Protective role of andrographolide in bleomycin-induced pulmonary fibrosis in mice.International journal of molecular sciences · 2013Article
- Evaluation of cytotoxic, genotoxic and inflammatory responses of nanoparticles from photocopiers in three human cell lines.Particle and fibre toxicology · 2013Article
- Role of migratory inhibition factor in age-related susceptibility to radiation lung injury via NF-E2-related factor-2 and antioxidant regulation.American journal of respiratory cell and molecular biology · 2013Article
- Article
- The role of macrophages in healing the wounded lung.International journal of experimental pathology · 2012Review
- Biomarkers of fibroproliferative healing in fibrosing idiopathic interstitial pneumonias.The open respiratory medicine journal · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a severe, rapidly progressive diffuse lung disease. Several pathogenetic mechanisms have been hypothesized on the basis of the fibrotic lung damage occurring in this disease, and a potential profibrotic role of activated alveolar macrophages and their mediators in the pathogenesis of IPF was recently documented. This paper focuses on recent literature on potential biomarkers of IPF derived from activated alveolar macrophages. Biomarker discovery and clinical application are a recent topic of interest in the field of interstitial lung diseases (ILDs). Cytokines, CC-chemokines, and other macrophage-produced mediators are the most promising prognostic biomarkers. Many molecules have been proposed in the literature as potential biomarker of IPF; however, a rigorous validation is needed to confirm their clinical utility.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.